2cureX provides update regarding the COVID-19 impact on ongoing clinical programs
Copenhagen — March 23, 2020 — 2cureX AB (“2cureX”, NASDAQ: 2CUREX) announced today that the corona-crisis will not delay 2cureX’s intervention study where the IndiTreat test is guiding treatment of patients with metastatic colorectal cancer (ClinicalTrials.gov Identifier: NCT03251612). Patient recruitment will continue as planned and finalization of the trial is expected as previously communicated in Q3 of 2020.Vejle University Hospital has informed 2cureX that patient recruitment for the metastatic colorectal cancer trial will be upheld. The project is in its late stage and patient